NONI: Inhaled nitric oxide to reduce reperfusion injury in myocardial infarction

Infarct size is an independent predictor of survival and ventricular function. Several alternatives have been tried to reduce the size of the infarcted area and its consequences. Small pilot studies suggest that inhaled nitric oxide may improve reperfusion in acute myocardial infarction with ST-segment elevation. Patients were randomized to conventional treatment versus inhalation of 80 ppm nitric oxide in the cath lab while performing primary angioplasty. Nitric oxide did not significantly reduce infarct area. 

11_michael_marber
Michael Marber
2014-09-01

Original title: Nitric oxide for inhalation to reduce reperfusion injury in acute st-elevation myocardial infarction, NONI study.

 

More articles by this author

ATLANTIC: administration of ticagrelor in the ambulance versus in the cath lab

The platelet P2Y12 receptor antagonist ticagrelor is shown to reduce the incidence of cardiovascular events when administered in hospital admission to patients suffering an...

MITOCARE: TRO40303 intravenous infusion in the context of primary angioplasty

Prospective, multicenter, randomized, double-blind study evaluated intravenous infusion of TRO40303 versus placebo administered immediately before balloon dilation of the culprit artery during primary angioplasty....

FAMOUS NSTEMI: FFR versus Angiography in non-ST segment elevation myocardial infarction

The benefit of myocardial revascularization (angioplasty or surgery) guided by fractional flow reserve (FFR) in the context of acute coronary syndromes is poorly studied...

CULPRIT: Complete revascularization versus culprit artery of infarct only

Current guidelines suggest treating only the culprit artery of myocardial infarction with ST-segment elevation. This prospective and randomized work included 296 patients in 7...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TricValve Transcatheter Bicaval Valve System for Severe Tricuspid Insufficiency: Events at One Year

TricValve is the first bicaval valve system to obtain CE-Mark approval. This device heterotopic device eliminates tricuspid insufficiency reflux into the venous system, reducing...

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...